Compare Booz Allen Hamilton Holding Corporation (BAH) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs BIO-TECHNE Corp — how do they compare? Booz Allen Hamilton Holding Corporation trades at $63.65 (market cap $7.77B), while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and Booz Allen Hamilton Holding Corporation pays the higher dividend (3.64%). Which is the better fit depends on your goals.
| BAH | TECH | |
|---|---|---|
Market Cap | $7.77B | $11.12B |
Sector | Industrials | Health |
52-Week High | $115.95 | $71.38 |
52-Week Low | $59.71 | $43.31 |
Enterprise Value | $11.17B | $11.20B |
Dividend Yield | 3.64% | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
